We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Blue Light Cystoscopy With Cysview® Registry (BLCCR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02660645
Recruitment Status : Recruiting
First Posted : January 21, 2016
Last Update Posted : October 25, 2021
Information provided by (Responsible Party):

Brief Summary:
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

Condition or disease Intervention/treatment
Bladder Cancer Drug: Hexaminolevulinate hydrochloride (HCL) Device: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system

Detailed Description:

Data will be captured on specific patient types undergoing Blue Light Cystoscopy with Cysview for known or suspected non-muscle invasive bladder cancer. Specific clinical questions will be asked.

  1. What is the incremental detection rate with Blue Light Cystoscopy with Cysview over conventional white light cystoscopy in each of the seven (7) patient populations? Does this translate into lower recurrence/progression rate?
  2. How do the six (6) tumor variables used in the European Association of Urology (EAU) risk tables (primary/secondary, recurrence rate, size, multifocality, grade, and history of carcinoma in situ (CIS))6 affect this incremental rate?
  3. How does an abnormal cytology or positive or negative fluorescent in situ hybridization (FISH) affect the likelihood that Blue Light Cystoscopy with Cysview will detect more cancers than white light?
  4. What are the performance characteristics of Blue Light Cystoscopy with Cysview within eight (8) weeks of Bacillus Calmette-Guérin (BCG) with respect to improved tumor detection and false positive rate compared to conventional white light cystoscopy?
  5. What is the incremental Blue Light Cystoscopy with Cysview detection rate over random bladder biopsies alone in patients being evaluated for routine three month restaging (group 4) or occult disease (group 5)?
  6. What are the performance characteristics of Blue Light Cystoscopy with Cysview after repeated Blue Light Cystoscopy with Cysview evaluations with respect to improved tumor detection, false positive rate and safety compared to conventional white light?
  7. Does an abnormal urinalysis help identify patients with inflammation more likely to have false positive Blue Light Cystoscopy with Cysview results?
  8. What is the practical learning curve for becoming "proficient" with Blue Light Cystoscopy with Cysview?
  9. What is the overall false positive rate with Blue Light Cystoscopy with Cysview?
  10. Can Blue Light Cystoscopy with Cysview make the resection more complete? If yes, is this due to improved margins and/or additional tumors seen under blue light?

The Blue Light Cystoscopy with Cysview Registry is a web-based program supported by Global Vision Technologies. Data will be captured longitudinally over five (5) years on patients from each enrolled site. Each center will enter their respective site's patient data electronically.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 4400 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Blue Light Cystoscopy With Cysview® Registry
Study Start Date : April 2014
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Blue Light Cystoscopy with Cysview®
Bladder cancer patients who have undergone Blue light cystoscopy with Hexaminolevulinate hydrochloride (Cysview®) 100mg in 50 milliliters (mL) reconstituted solution instilled intravesically into bladder prior to cystoscopy in operating room (OR). Retention time: 1-3 hours. The Karl Storz D-Light C Photodynamic Diagnostic (PDD) system is used for the cystoscopy procedure at the OR examination.
Drug: Hexaminolevulinate hydrochloride (HCL)
Instillation in bladder
Other Names:
  • Cysview®
  • Hexvix®

Device: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Cystoscopy procedure

Primary Outcome Measures :
  1. Rate of detection of bladder malignancies [ Time Frame: 5 years ]
    Rate of detection of bladder malignancies with Blue Light Cystoscopy with Cysview versus white light cystoscopy alone.

Secondary Outcome Measures :
  1. False-positive detection rates [ Time Frame: 5 years ]
    Rates of false-positive lesion biopsies based on pathological findings

  2. Higher-Quality resection rates with Blue Light Cystoscopy with Cysview versus white light cystoscopy alone [ Time Frame: 5 years ]
    Rate of additional margin detection with Blue Light Cystoscopy with Cysview versus white light cystoscopy alone

  3. Proportion of patients with adverse events considered causally related to Cysview in repeat administration. [ Time Frame: 5 years ]
    Adverse events reporting

  4. Recurrence Rates [ Time Frame: 5 years ]
    Recurrence rates NMIBC in patients whose lesions were detected with Blue Light Cystoscopy with Cysview

  5. Cystectomy Rate [ Time Frame: 5 years ]
    Proportion of patients who have a cystectomy performed

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients indicated for transurethral resection of the bladder.

Inclusion Criteria:

  • Adult >18 years old
  • Suspected or known non-muscle invasive bladder cancer on the basis of a prior cystoscopy

Exclusion Criteria:

  • Porphyria
  • Gross hematuria
  • Known hypersensitivity to hexaminolevulinate or aminolevulinate derivatives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02660645

Layout table for location contacts
Contact: Anthony Fernandez (609) 759 6500 af@photocure.com

Layout table for location information
United States, California
USC/Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Ileana Aldana    323-865-0702    ileana.aldana@med.usc.edu   
Principal Investigator: Sia Daneshmand, MD         
Sub-Investigator: Anne Schuckman, MD         
Sub-Investigator: Mihir Desai, MD         
Sub-Investigator: Hooman Djaladat, MD         
Sub-Investigator: Gerhard Fuchs, MD         
Sub-Investigator: Virinder Bhardwaj, MD         
VA Palo Alto Health Care System Recruiting
Palo Alto, California, United States, 94304
Contact: Dorothy Trivedi       dtrivedi@stanford.edu   
Principal Investigator: Joseph Liao, MD         
Sub-Investigator: James Crotty, MD         
Sub-Investigator: John Leppert, MD         
Sub-Investigator: John Lavelle, MD         
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Sima Porten, MD, MPH    415-885-3695    Sima.Porten@ucsf.edu   
Principal Investigator: Sima Porten, MD, MPH         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Katie Glavin    913-588-8721    kglavin@kumc.edu   
Principal Investigator: John Taylor, MD, MS         
Sub-Investigator: Jeffrey Holzbeierlein, MD, FACS         
Sub-Investigator: Eugene Lee, MD, FACS         
Sub-Investigator: Hadley Wyre, MD         
Sub-Investigator: Moben Mirza, MD         
United States, Maryland
Johns Hopkins Medicine Recruiting
Baltimore, Maryland, United States, 21224
Contact: Morgan De Carli       Mdecarl2@jhmi.edu   
Principal Investigator: Trinity Bivalacqua, MD, PhD         
Sub-Investigator: Phillip Pierorazio, MD         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Therese Perrier    612-625-3319    perri084@umn.edu   
Principal Investigator: Badrinath Konety, MD         
Sub-Investigator: Weight Chris, MD         
Sub-Investigator: Laureen Hemsley, MD         
United States, New York
Stony Brook Urology Suspended
Stony Brook, New York, United States, 11794
United States, Ohio
Cincinnati VA Medical Center Withdrawn
Cincinnati, Ohio, United States, 45220
Ohio State University Wexner Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Kamal Pohar, MD       kamal.pohar@osumc.edu   
Principal Investigator: Kamal Pohar, MD         
Sub-Investigator: Megan Merrill, DO         
Sub-Investigator: Ahmad Shabsigh, MD         
Sub-Investigator: David Sharp, MD         
United States, South Carolina
Carolina Urology Partners Recruiting
West Columbia, South Carolina, United States, 29169
Contact: Nicol Brandon    704-414-2870 ext 2809    Nicol.brandon@carolinaurologypartners.com   
Principal Investigator: T. Brian Willard, MD         
Sub-Investigator: David Lamb, MD         
Sub-Investigator: Scott Sweazy, MD         
Sub-Investigator: Keith Birghtbill, MD         
Sub-Investigator: Michael Stotzer, MD         
United States, Texas
UT Southwestern Not yet recruiting
Dallas, Texas, United States, 75390
Contact: Yair Lotan, MD    214-645-8787      
Principal Investigator: Yair Lotan, MD         
Sub-Investigator: Aditya Bagrodia, MD         
Sub-Investigator: Vitaly Margulis, MD         
Sub-Investigator: Ganesh Raj, MD, PhD         
Michael E. DeBakey VA Medical Center Recruiting
Houston, Texas, United States, 77030
Contact: Ashley Jones, BS, CCRP    713-791-1414 ext 26694    Ashley.Jones2@bcm.edu   
Principal Investigator: Jennifer Taylor, MD, MPH         
Sub-Investigator: Jeffrey Jones, MD         
Sub-Investigator: Sidney Worsham, MD         
United States, West Virginia
Charleston Area Medical Center Terminated
Charleston, West Virginia, United States, 25301
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Siamak Daneshmand, MD University of Southern California
Additional Information:

Publications of Results:
Bazargani ST, Shah SH, Djaladat H, et al. Blue Light Cystoscopy For Diagnosis of Urothelial Bladder Cancer: Results: From A Prospective Registry. Poster presented at: The Annual meeting of Society of Urologic Oncology; December 2015; Washington, D.C.

Layout table for additonal information
Responsible Party: Photocure
ClinicalTrials.gov Identifier: NCT02660645    
Other Study ID Numbers: BLCCR-001
First Posted: January 21, 2016    Key Record Dates
Last Update Posted: October 25, 2021
Last Verified: October 2021
Keywords provided by Photocure:
Blue Light Cystoscopy with Cysview
Fluorescent cystoscopy
Non-muscle invasive bladder cancer (NMIBC)
Transurethral resection (TUR)
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents